MT
MTNB.US Matinas BioPharma Holdings Inc
- Market cap
- USD 882K
- P/E
- -
- P/B
- 0.49x
- ROE
- -360.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is MTNB.US undervalued?
Graham numberThe Graham number of Matinas BioPharma Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Matinas BioPharma Holdings Inc fundamental analysis
No fundamental analysis for Matinas BioPharma Holdings Inc yet.
Matinas BioPharma Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Matinas BioPharma Holdings Inc
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for…
Full company profileMatinas BioPharma Holdings Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Matinas BioPharma Holdings Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 150K | 120K | 89.8K | 158K | 33.0K | 3.19M | 1.10M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -52.6K | -8.86M | -6.67M | -11.1M | -14.2M | -14.6M | -13.5M | 155K | -972K | -456K | -156K |
| Operating Income | -8.26M | -16.5M | -14.6M | -18.9M | -24.2M | -24.7M | -24.6M | -23.8M | -20.2M | -6.96M | -6.98M |
| EBITDA | -8.20M | -16.4M | -14.4M | -18.1M | -23.4M | -22.5M | -20.1M | -22.0M | -19.2M | -9.89M | -7.25M |
| Net Income | -7.60M | -15.5M | -14.1M | -17.4M | -22.4M | -23.3M | -21.0M | -22.9M | -24.3M | -10.3M | -6.49M |
| EPS | -0.13 | -128 | -0.14 | -90 | -86 | -83 | -73 | -79 | -75 | -28 | -15 |
| Balance Sheet | |||||||||||
| Total Assets | 9.82M | 14.4M | 19.9M | 40.2M | 71.0M | 61.3M | 78.9M | 25.1M | 12.6M | 7.21M | 3.41M |
| Total Liabilities | 2.67M | 3.74M | 3.80M | 7.19M | 7.24M | 8.83M | 42.2M | 5.86M | 5.05M | 2.38M | 1.61M |
| Shareholders' Equity | 7.15M | 10.7M | 16.1M | 33.1M | 63.7M | 52.5M | 36.6M | 19.2M | 7.59M | 4.83M | 1.80M |
| Cash & Short-term Investments | 4.11M | 7.31M | 12.4M | 27.8M | 58.7M | 49.6M | 28.8M | 13.8M | 7.28M | 4.00M | 761K |
| Total Debt | 144K | 265K | 391K | 4.23M | 3.75M | 4.70M | 4.12M | 3.56M | 2.89M | 1.35M | 6.00K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -6.12M | -11.5M | -10.3M | -14.1M | -17.4M | -15.2M | -19.2M | -15.3M | -15.9M | -7.01M | -6.87M |
| Capital Expenditure | 942K | 942K | 536K | 406K | 5.75K | 260K | 892K | 218K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -6.12M | -12.4M | -10.9M | -14.5M | -17.4M | -15.5M | -20.0M | -15.5M | -15.9M | -7.01M | -6.87M |
| Ratios | |||||||||||
| ROE | -106.3% | -145.0% | -87.2% | -52.6% | -35.2% | -44.4% | -57.3% | -119.2% | -319.5% | -214.2% | -360.8% |
| ROA | -77.4% | -107.4% | -70.6% | -43.2% | -31.6% | -38.0% | -26.6% | -91.4% | -191.8% | -143.5% | -190.3% |
| Net Profit Margin | - | -10,345.9% | -11,760.4% | -19,343.4% | -14,177.0% | -70,554.5% | -658.6% | -2,093.2% | - | - | - |
| Debt to Equity | 0.02x | 0.02x | 0.02x | 0.13x | 0.06x | 0.09x | 0.11x | 0.18x | 0.38x | 0.28x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Matinas BioPharma Holdings Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 844M | 3,010 | - |
| 2020 | USD 683M | 2,601 | - |
| 2019 | USD 2.23B | 11,542 | - |
| 2018 | USD 587M | 5.98 | - |
| 2017 | USD 608M | 5,043 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:15 on Sep 28, 2026.
Who owns Matinas BioPharma Holdings Inc
- Insiders 23.77%
- Institutions 1.19%
- Public & others 75.04%
- Shares outstanding 980K
- Free float 775K
Matinas BioPharma Holdings Inc company profile
- Company name
- Matinas BioPharma Holdings Inc
- Ticker
- MTNB.US
- Exchange
- USA Stocks
- Listed since
- Aug 18, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- December
- Address
- 1545 Route 206 South, Bedminster, NJ, United States, 07921
- Phone
- 908 484 8805
- Website
- matinasbiopharma.com
About Matinas BioPharma Holdings Inc
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Matinas BioPharma Holdings Inc management
1- Mr. Jerome D. Jabbour J.D.Co-Founder, Chairman, CEO, President & Interim CFO · born 1974